WELIREG™ (belzutifan) | Official Patient Website
What are the ingredients in WELIREG? Active ingredient: belzutifan Inactive ingredients: croscarmellose sodium, hypromellose acetate succinate, magnesium stearate, mannitol, microcrystalline cellulose, and silicon dioxide. The film-coating contains FD&C Blue #2 aluminum lake, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide. Please read the …
Belzutifan (Welireg™) | OncoLink
25/08/2021 · Belzutifan (Welireg™) is a hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor used for the treatment of von Hippel-Lindau (VHL) disease. In VHL, the body overproduces HIF-2α, leading to an increased risk of cancer cell development/growth. Belzutifan (Welireg™) works to block these mechanisms that make cells reproduce rapidly, and influence tumor growth. How …
Videos Of Welireg (Belzutifan)
Welireg™ (belzutifan) Is Available From Onco360! WELIREG ™ (belzutifan) is a hypoxia-inducible factor inhibitor indicated for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring …
WELIREG™ (belzutifan) | Official Site
Belzutifan (Welireg™) | OncoLink
Welireg™ (belzutifan) - Onco360
Belzutifan (Welireg™) | OncoLink
FDA Approves Belzutifan For Cancers Associated With Von …
FDA approves belzutifan for cancers associated with von ...
Welireg (Belzutifan Tablets): Uses, Dosage, Side Effects, …
Belzutifan - Wikipedia
WARNINGS AND PRECAUTIONS ----------------------
01/02/2022 · FDA approves belzutifan for cancers associated with von Hippel-Lindau disease. On August 13, 2021, the Food and Drug Administration approved belzutifan (Welireg, Merck), a hypoxia-inducible factor ...
Belzutifan - Wikipedia
22/10/2021 · WELIREG is supplied as blue, film-coated tablets for oral use containing 40 mg of belzutifan together with croscarmellose sodium, hypromellose acetate succinate, magnesium stearate, mannitol, microcrystalline cellulose, and silicon dioxide, as inactive ingredients. In addition, the film-coating contains FD&C Blue #2 aluminum lake, polyethylene glycol, polyvinyl …
HIGHLIGHTS OF PRESCRIBING INFORMATION Anemia
for WELIREG. WELIREG. TM (belzutifan) tablets, for oral use Initial U.S. Approval: 2021 . WARNING: EMBRYO-FETAL TOXICITY . See full prescribing information for complete boxed warning. • Exposure to WELIREG during pregnancy can cause embryo-fetal harm. • Verify pregnancy status prior to the initiation of WELIREG. • Advise patients of these risks and the …
Images Of Welireg Belzutifan
Belzutifan, sold under the brand name Welireg, is a medication used for the treatment of von Hippel–Lindau disease-associated renal cell carcinoma. It is taken by mouth. The most common side effects include decreased hemoglobin, anemia, fatigue, increased creatinine, headache, dizziness, increased glucose, and nausea.